目次
1. 市場の紹介と範囲
1.1. レポートの目的
1.2. レポートの対象範囲と定義
1.3. レポートの範囲
2. 経営陣の見解と主な結論
2.1. 市場のハイライトと戦略的結論
2.2. 主な傾向と将来予測
2.3. 製品の種類別抜粋
2.4. テクノロジー別抜粋
2.5. 用途別
2.6. エンドユーザー別
2.7. 地域別
3. ダイナミクス
3.1. 影響因子
3.1.1. 推進要因
3.1.1.1. ゲノム技術の進歩
3.1.1.2. 精密腫瘍学へのシフト
3.1.2. 阻害要因
3.1.2.1. データ統合の複雑性
3.1.3. 機会
3.1.4. 影響分析
4. 戦略的洞察および業界展望
4.1. 市場リーダーおよび先駆者
4.1.1. 新興の先駆者および著名な企業
4.1.2. 最大販売ブランドを持つ確立されたリーダー
4.1.3. 確立された製品を持つ市場リーダー
4.2. 新興のスタートアップ企業と主要イノベーター
4.3. CXOの見解
4.4. 最新の動向と画期的な進歩
4.5. ケーススタディ/進行中の研究
4.6. 規制と償還の概観
4.6.1. 北米
4.6.2. ヨーロッパ
4.6.3. アジア太平洋
4.6.4. ラテンアメリカ
4.6.5. 中東およびアフリカ
4.7. ポーターのファイブフォース分析
4.8. サプライチェーン分析
4.9. 特許分析
4.10. SWOT分析
4.11. 未充足ニーズとギャップ
4.12. 市場参入および市場拡大のための推奨戦略
4.13. シナリオ分析：最善のケース、基本ケース、最悪のケースの予測
4.14. 価格分析および価格力学
5. 製品種類別、超個別化医療市場
5.1. はじめに
5.1.1. 市場規模分析および前年比成長率（％）、製品種類別
5.1.2. 製品種類別市場魅力度指数
5.2. 治療*
5.2.1. はじめに
5.2.2. 市場規模分析および前年比成長率分析（％）
5.3. 診断
5.4. ソフトウェアソリューション
6. 技術別超個別化医療市場
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（％）、技術別
6.1.2. 市場魅力度指数、技術別
6.2. ゲノミクス*
6.2.1. はじめに
6.2.2. 市場規模分析および前年比成長率分析（％）
6.3. プロテオミクス
6.4. バイオインフォマティクス
6.5. 人工知能（AI）
6.6. その他
7. 用途別 超個別化医療市場
7.1. はじめに
7.1.1. 用途別 市場規模分析および前年比成長率（％）
7.1.2. 用途別 市場魅力度指数
7.2. 腫瘍学*
7.2.1. はじめに
7.2.2. 市場規模分析および前年比成長率分析（％）
7.3. 循環器学
7.4. 神経学
7.5. 免疫学
7.6. 希少疾患
7.7. 感染症
7.8. その他
8. 超個別化医療市場、エンドユーザー別
8.1. はじめに
8.1.1. エンドユーザー別市場規模分析および前年比成長率（％）
8.1.2. エンドユーザー別市場魅力度指数
8.2. 病院*
8.2.1. はじめに
8.2.2. 市場規模分析および前年比成長率（％）
8.3. 専門クリニック
8.4. 診断センター
8.5. 在宅医療
8.6. その他
9. 地域別市場分析と成長機会による超個別化医療市場
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率（％）
9.1.2. 地域別市場魅力度指数
9.2. 北米
9.2.1. はじめに
9.2.2. 主な地域特有の動向
9.2.3. 市場規模分析および前年比成長率（％）製品種類別
9.2.4. 市場規模分析および前年比成長率（％）技術別
9.2.5. 市場規模分析および前年比成長率（％）用途別
9.2.6. エンドユーザー別市場規模分析および前年比成長率分析（％）
9.2.7. 国別市場規模分析および前年比成長率分析（％）
9.2.7.1. 米国
9.2.7.2. カナダ
9.2.7.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主要地域別の動向
9.3.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.3.4. 市場規模分析および前年比成長率分析（％）、技術別
9.3.5. 市場規模分析および前年比成長率分析（％）、用途別
9.3.6. エンドユーザー別市場規模分析および前年比成長率分析（％）
9.3.7. 国別市場規模分析および前年比成長率分析（％）
9.3.7.1. ドイツ
9.3.7.2. 英国
9.3.7.3. フランス
9.3.7.4. スペイン
9.3.7.5. イタリア
9.3.7.6. ヨーロッパのその他地域
9.4. 南アメリカ
9.4.1. はじめに
9.4.2. 主要地域特有の動向
9.4.3. 市場規模分析および前年比成長率（％）、製品種類別
9.4.4. 市場規模分析および前年比成長率（％）、技術別
9.4.5. 市場規模分析および前年比成長率（％）、用途別
9.4.6. 市場規模分析および前年比成長率（％）、エンドユーザー別
9.4.7. 市場規模分析および前年比成長率（％）、国別
9.4.7.1. ブラジル
9.4.7.2. アルゼンチン
9.4.7.3. 南米その他
9.5. アジア太平洋地域
9.5.1. はじめに
9.5.2. 主要地域特有の動向
9.5.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.5.4. 市場規模分析および前年比成長率（％）、技術別
9.5.5. 市場規模分析および前年比成長率（％）、用途別
9.5.6. 市場規模分析および前年比成長率（％）、エンドユーザー別
9.5.7. 市場規模分析および前年比成長率（％）、国別
9.5.7.1. 中国
9.5.7.2. インド
9.5.7.3. 日本
9.5.7.4. 韓国
9.5.7.5. アジア太平洋地域その他
9.6. 中東およびアフリカ
9.6.1. はじめに
9.6.2. 主要地域特有の動向
9.6.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.6.4. 市場規模分析および前年比成長率分析（％）、技術別
9.6.5. 市場規模分析および前年比成長率分析（％）、用途別
9.6.6. 市場規模分析および前年比成長率分析（％）、エンドユーザー別
10. 競合状況と市場ポジショニング
10.1. 競合の概要と主要市場プレーヤー
10.2. 市場シェア分析とポジショニングマトリクス
10.3. 戦略的提携、合併および買収
10.4. 製品ポートフォリオとイノベーションにおける主な進展
10.5. 企業間比較
11. 企業プロフィール
AstraZeneca PLC
GE HealthCare
Illumina, Inc.
Novartis AG
Precision Biologics.
Abbott Laboratories
ASURAGEN, INC.
F. Hoffmann-La Roche Ltd.
Achilles Therapeutics plc
QIAGEN N.V.
(リストは網羅的なものではありません)
12. 仮定と調査方法
12.1. データ収集方法
12.2. データの三角測量
12.3. 予測の処置
12.4. データ検証と妥当性確認
13. 付録
13.1. 当社とサービスについて
13.2. お問い合わせ
The global hyper personalized medicine market reached US$ 419.3 billion in 2023 and is expected to reach US$ 799.5 billion by 2031, growing at a CAGR of 8.5% during the forecast period 2024-2031.
Hyper personalized medicine is an advanced healthcare approach that tailors medical treatment and preventive strategies to individual patients based on their unique biological, genetic, environmental and lifestyle factors. It goes beyond traditional medical practices by utilizing cutting-edge technologies like genomics, proteomics, metabolomics and bioinformatics to offer treatments that are highly specific to the molecular and cellular characteristics of each patient. This approach is revolutionizing healthcare by improving outcomes, reducing side effects and enabling preventive measures based on predictive insights.
The demand for hyper personalized medicine is rapidly expanding. For instance, according to the Personalized Medicine Coalition (PMC), With the approval of 17 new personalized medicines in 2021, personalized medicines, account for more than a quarter of the new drugs the agency has approved in, the past seven years. This figure represents a sharp recent increase. Just a decade ago, personalized medicines accounted for less than 10 percent of the new therapies approved each year. This market is set to transform healthcare delivery by integrating advanced technologies with precise, patient-centered care models, ensuring better outcomes and efficiency.
Market Dynamics: Drivers & Restraints
Rising advancements in genomic technologies
Rising advancements in genomic technologies are significantly driving the growth of the hyper personalized medicine market and are expected to drive the market over the forecast period. Technologies like Next-Generation Sequencing (NGS) have drastically reduced the cost and time needed for genome sequencing. According to the J. Craig Venter Institute, the cost of sequencing a human genome has dropped from over USD 100 million in 2001 to less than USD 1,000 today and takes only a few hours, making personalized medicine more accessible to a broader population.
Major market players are focussing on the development of hyper personalized medicine approaches, which further fueling the market growth. For instance, in March 2024, Nucleus Genomics, the next-generation genetic testing and analysis company, launched its DNA analysis product to bring the benefits of personalized medicine to everyone. Nucleus combined the power of whole-genome sequencing with innovative genomic analyses, ushering in a new era of personalized medicine for the public.
CRISPR gene-editing technology is enabling the development of personalized therapies by directly targeting the genetic causes of diseases. Companies are using CRISPR to explore treatments for genetic disorders such as sickle cell anemia and muscular dystrophy, offering highly personalized and potentially curative treatments.
For instance, in May 2024, Researchers at Columbia University College of Dental Medicine developed an exosome-based platform, "safeEXO-Cas," that significantly enhances the delivery of CRISPR/Cas9 genome editing components to specific cells and tissues. The potential of this innovative platform is to revolutionize gene therapy and precision medicine.
Complexity of data integration
The complexity of data integration is expected to hamper the growth of the hyper personalized medicine market. This issue primarily arises from the integration of vast and varied datasets, which include genomic, proteomic, clinical and environmental data. These challenges impact the ability to efficiently develop personalized treatment plans, slowing the adoption of hyper personalized medicine.
Personalized medicine requires the integration of large-scale data from different sources like electronic health records (EHRs), genomic sequencing, medical imaging and real-time monitoring devices. These data types are often siloed across systems and lack standardization, making it difficult to draw comprehensive insights. For instance, genomic data might be stored in one system, while clinical data is in another, and patient health records are stored in yet another platform. This lack of uniformity complicates the creation of a cohesive, actionable profile for individual patients.
Healthcare systems across different regions often use incompatible technologies, leading to poor interoperability between electronic health systems. For instance, a report by the American Health Information Management Association (AHIMA) indicates that 80% of healthcare organizations in the U.S. experience data integration issues, which directly affects the efficiency of personalized treatments.
Segment Analysis
The global hyper personalized medicine market is segmented based on product type, technology, application, end-user and region.
Application:
The oncology segment is expected to dominate the hyper personalized medicine market share
The oncology segment is expected to dominate the global hyper personalized medicine market. Cancer is one of the most prevalent diseases worldwide. The increasing prevalence directly increases the demand for effective treatments, particularly in the face of diverse tumor types, this has accelerated the shift toward personalized oncology.
For instance, according to the National Institute of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Personalized approaches in oncology allow for targeting specific mutations in tumors, offering better outcomes and reducing side effects compared to traditional treatments.
The use of genomic profiling in oncology allows for identifying genetic mutations that drive cancer progression, enabling more accurate diagnoses and targeted treatments. Technologies like Next-Generation Sequencing (NGS) are extensively used to analyze tumor genomes. For instance, FoundationOne by Foundation Medicine offers comprehensive genomic profiling of solid tumors to identify actionable mutations, guiding the selection of targeted therapies.
Geographical Analysis
North America is expected to hold a significant position in the hyper personalized medicine market share
North America is expected to hold the largest market share in the global hyper personalized medicine market. North America, particularly the United States is a global leader in biomedical research, accounting for approximately 60% of the world's total healthcare R&D spending. Significant funding is provided for the development of precision medicine technologies, including genomic profiling, bioinformatics and digital health solutions.
North America benefits from a robust regulatory environment, particularly through organizations like the FDA (Food and Drug Administration) in the United States. The FDA has approved several personalized therapies such as CAR-T cell treatments such as Kymriah for leukemia and checkpoint inhibitors such as Keytruda for various cancers. These approvals drive market growth by providing a clear pathway for the development and commercialization of hyper personalized medicines.
North America leads the adoption of advanced technologies like artificial intelligence (AI), which are pivotal in the development of personalized medicine. For instance, in October 2024, Ataraxis AI emerged from stealth with $4 million. The funding has enabled Ataraxis to develop groundbreaking AI-powered diagnostic tests that significantly enhance the prediction of patient outcomes and enable more precise, personalized treatments. The company also unveiled its first offering, Ataraxis Breast – the world’s first AI-native prognostic/predictive test for breast cancer and the most advanced clinically validated test available.
Asia-Pacific is growing at the fastest pace in the hyper personalized medicine market
The Asia-Pacific region is experiencing the fastest growth in the hyper personalized medicine market. The incidence of chronic diseases, such as cancer, diabetes and cardiovascular diseases, is rising in the Asia Pacific region. For instance, according to ScienceDirect, about 4,824,700 new cancer cases and 2,574,200 new cancer deaths occurred in China in 2022. Similarly, according to the National Institute of Health, it is predicted that by 2030 diabetes mellitus may afflict up to 79.4 million individuals in India, while China with 42.3 million. As chronic diseases become more prevalent, there is a greater need for targeted therapies, genomic diagnostics and personalized treatment approaches that are central to hyper personalized medicine.
The Asia Pacific region is increasingly adopting artificial intelligence (AI) to analyze patient data, enabling the creation of highly personalized treatment plans. Companies in countries like Japan, India and South Korea are integrating AI with genomic technologies to improve cancer diagnosis and treatment plans.
For instance, in January 2024, GeneConnectRx, an innovative artificial intelligence (AI) platform launched by GenepoweRx, the diagnostic wing of the K&H clinic. This revolutionary step in personalized medicine marks a paradigm shift, empowering healthcare providers to customize treatments based on individual genetic makeup.
Competitive Landscape
The major global players in the hyper personalized medicine market are AstraZeneca PLC, GE HealthCare, Illumina, Inc., Novartis AG, Precision Biologics., Abbott Laboratories, ASURAGEN, INC., F. Hoffmann-La Roche Ltd., Achilles Therapeutics plc, QIAGEN N.V. and among others.
Why Purchase the Report?
• Pipeline & Innovations: Insights into clinical trials, product pipelines, and upcoming advancements.
• Market Positioning: Analysis of product performance and growth potential for optimized strategies.
• Real-World Evidence: Integration of patient feedback for enhanced product outcomes.
• Physician Preferences: Insights into healthcare provider behaviors and adoption strategies.
• Regulatory & Market Updates: Coverage of recent regulations, policies, and emerging technologies.
• Competitive Insights: Analysis of market share, competitor strategies, and new entrants.
• Pricing & Market Access: Review of pricing models, reimbursement trends, and access strategies.
• Market Expansion: Strategies for entering new markets and forming partnerships.
• Regional Opportunities: Identification of high-growth regions and investment prospects.
• Supply Chain Optimization: Assessment of risks and distribution strategies.
• Sustainability & Regulation: Focus on eco-friendly practices and regulatory changes.
• Post-Market Surveillance: Enhanced safety and access through post-market data.
• Value-Based Pricing: Insights into pharmacoeconomics and data-driven R&D decisions.
The global hyper personalized medicine market report delivers a detailed analysis with 70 key tables, more than 70 visually impactful figures, and 189 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies
• Academic & Research: Academic Institutions.
Table of Contents
1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by Application
2.6. Snippet by End-User
2.7. Snippet by Region
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Advancements in Genomic Technologies
3.1.1.2. Shift Towards Precision Oncology
3.1.2. Restraints
3.1.2.1. Complexity of Data Integration
3.1.3. Opportunity
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest selling Brand
4.1.3. Market leaders with established Product
4.2. Emerging Startups and Key Innovators
4.3. CXO Perspectives
4.4. Latest Developments and Breakthroughs
4.5. Case Studies/Ongoing Research
4.6. Regulatory and Reimbursement Landscape
4.6.1. North America
4.6.2. Europe
4.6.3. Asia Pacific
4.6.4. Latin America
4.6.5. Middle East & Africa
4.7. Porter’s Five Force Analysis
4.8. Supply Chain Analysis
4.9. Patent Analysis
4.10. SWOT Analysis
4.11. Unmet Needs and Gaps
4.12. Recommended Strategies for Market Entry and Expansion
4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.14. Pricing Analysis and Price Dynamics
5. Hyper Personalized Medicine Market, By Product Type
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Therapeutics*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Diagnostics
5.4. Software Solutions
6. Hyper Personalized Medicine Market, By Technology
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index, By Technology
6.2. Genomics*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Proteomics
6.4. Bioinformatics
6.5. Artificial Intelligence (AI)
6.6. Others
7. Hyper Personalized Medicine Market, By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Oncology*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiology
7.4. Neurology
7.5. Immunology
7.6. Rare Disorders
7.7. Infectious Diseases
7.8. Others
8. Hyper Personalized Medicine Market, By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Diagnostic Centers
8.5. Homecare Settings
8.6. Others
9. Hyper Personalized Medicine Market, By Regional Market Analysis and Growth Opportunities
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape and Market Positioning
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. Company Profiles
11.1. AstraZeneca PLC*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.2. GE HealthCare
11.3. Illumina, Inc.
11.4. Novartis AG
11.5. Precision Biologics.
11.6. Abbott Laboratories
11.7. ASURAGEN, INC.
11.8. F. Hoffmann-La Roche Ltd
11.9. Achilles Therapeutics plc
11.10. QIAGEN N.V. (LIST NOT EXHAUSTIVE )
12. Assumption and Research Methodology
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. Appendix
13.1. About Us and Services
13.2. Contact Us
*** 超個別化医療の世界市場に関するよくある質問(FAQ) ***
・超個別化医療の世界市場規模は？
→DataM Intelligence社は2023年の超個別化医療の世界市場規模を4193億米ドルと推定しています。
・超個別化医療の世界市場予測は？
→DataM Intelligence社は2031年の超個別化医療の世界市場規模を7995億米ドルと予測しています。
・超個別化医療市場の成長率は？
→DataM Intelligence社は超個別化医療の世界市場が2024年～2031年に年平均8.5%成長すると展望しています。
・世界の超個別化医療市場における主要プレイヤーは？
→「AstraZeneca PLC、GE HealthCare、Illumina, Inc.、Novartis AG、Precision Biologics.、Abbott Laboratories、ASURAGEN, INC.、F. Hoffmann-La Roche Ltd.、Achilles Therapeutics plc、QIAGEN N.V.など ...」を超個別化医療市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
